GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Digoxin immune Fab (ovine) - DIGIFAB intravenous antidote

DIGIFAB / digoxin immune Fab

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Preserve early potassium monitoring and distinguish free from total digoxin

The RX general paragraph says especially after the first several hours; its laboratory paragraph and February 2026 manufacturer label say during the first several hours.

Before applying: Do not delay early potassium surveillance. Prolonged renal observation and free-digoxin assessment are separate from a misleading post-Fab total concentration.

Evidence for this qualification

Selected-source qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Digoxin immune Fab (ovine) - DIGIFAB intravenous antidote

Product / population
DIGIFAB for life-threatening or potentially life-threatening digoxin toxicity; this renal-monitoring record is not an antidote dose calculator.
Renal measure
Qualitative severe renal failure; no inferred CrCl bands
Before using this finding

Preserve early potassium surveillance and prolonged recurrence monitoring; distinguish free from total digoxin.

Selected named sections only; not a complete monograph or independent clinical approval.

Selected exact-product labeling sections read. Original-source bytes and complete revision histories were not retained or reconciled; retrieval does not establish current product availability.

Renal dosing, restrictions and evidence limits

In severe renal failure, observe for recurrent digitalis toxicity over a prolonged period; free/unbound digoxin may be useful. Total-digoxin assays can remain misleading for days or at least a week when kidney function is markedly impaired. A post-treatment total rise largely reflects Fab-bound digoxin, not active unbound exposure. Obtain a pretreatment sample when possible and monitor ECG, blood pressure and potassium. Follow potassium closely, especially during the first several hours, because reversal can produce rapid hypokalemia. The selected label does not specify a fixed renal observation duration or replacement dose.

Source revision: 02/2026 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://digifab.health/getmedia/20260204/87131120_20251_NO_V1_DigiFab%20Package%20Insert.pdf

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

Digoxin immune Fab (ovine) - DIGIFAB intravenous antidote

Authored v6.0; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

GlobalRPh RX List - DIGIFAB

Authored v6.0; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Digoxin immune Fab (ovine) - DIGIFAB intravenous antidote

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.
Before using this finding

Preserve early potassium surveillance and prolonged recurrence monitoring; distinguish free from total digoxin.

Dialysis evidence: No dialysis regimen established in selected content

DIGIFAB for life-threatening or potentially life-threatening digoxin toxicity; this renal-monitoring record is not an antidote dose calculator.

Renal method: Qualitative severe renal failure; no inferred CrCl bands
Retrieved: 2026-09-10

GlobalRPh RX List

GlobalRPh RX List - DIGIFAB

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.
Before using this finding

Do not use post-Fab total digoxin alone to infer persistent toxicity or a new antidote dose.

Dialysis evidence: No dialysis regimen established in selected content

DIGIFAB for life-threatening or potentially life-threatening digoxin toxicity; this renal-monitoring record is not an antidote dose calculator.

Renal method: Qualitative severe renal failure; no CrCl interval or reduction schedule
Retrieved: 2026-09-10

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

monitoring timing and assay interference

Preserve early potassium monitoring and distinguish free from total digoxin

The RX general paragraph says especially after the first several hours; its laboratory paragraph and February 2026 manufacturer label say during the first several hours.

How to use this: Do not delay early potassium surveillance. Prolonged renal observation and free-digoxin assessment are separate from a misleading post-Fab total concentration.

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/digifab-drug/

Exact product and population

DIGIFAB for life-threatening or potentially life-threatening digoxin toxicity; this renal-monitoring record is not an antidote dose calculator.

RDM60-SCOPE-digoxin-immune-fab-digifab · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Digoxin immune Fab (ovine) - DIGIFAB intravenous antidote

Open original reference

Open / share this exact local source

Salvagenix Inc. / manufacturer prescribing information · DIGIFAB for life-threatening or potentially life-threatening digoxin toxicity; this renal-monitoring record is not an antidote dose calculator.

Renal method: Qualitative severe renal failure; no inferred CrCl bands
Source date: 02/2026
Retrieved: 2026-09-10

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.
Before using this finding

Preserve early potassium surveillance and prolonged recurrence monitoring; distinguish free from total digoxin.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

In severe renal failure, observe for recurrent digitalis toxicity over a prolonged period; free/unbound digoxin may be useful. Total-digoxin assays can remain misleading for days or at least a week when kidney function is markedly impaired. A post-treatment total rise largely reflects Fab-bound digoxin, not active unbound exposure. Obtain a pretreatment sample when possible and monitor ECG, blood pressure and potassium. Follow potassium closely, especially during the first several hours, because reversal can produce rapid hypokalemia. The selected label does not specify a fixed renal observation duration or replacement dose.

RDM60-official-digoxin-immune-fab-digifab-87650ae3ee-C1 · Source locator: PDF page 2: 5.3-5.4; page 1: 5.1 and revision; both pages rendered

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

Selected exact-product labeling sections read. Original-source bytes and complete revision histories were not retained or reconciled; retrieval does not establish current product availability.

Source identity and provenance
Source family
product_label
Source
https://digifab.health/getmedia/20260204/87131120_20251_NO_V1_DigiFab%20Package%20Insert.pdf
Retrieved
2026-09-10
Exact label title
Digoxin immune Fab (ovine) - DIGIFAB intravenous antidote
Labeler
Salvagenix Inc.
Label revision
02/2026
Renal-function method
Qualitative severe renal failure; no inferred CrCl bands
Source date/version
02/2026
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
30a625c812835cdbfcfcfeecefe1a5d673017ab4b083ffcf1e7e5e2cbc0209de
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - DIGIFAB

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · DIGIFAB for life-threatening or potentially life-threatening digoxin toxicity; this renal-monitoring record is not an antidote dose calculator.

Renal method: Qualitative severe renal failure; no CrCl interval or reduction schedule
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.
Before using this finding

Do not use post-Fab total digoxin alone to infer persistent toxicity or a new antidote dose.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Severe renal failure warrants prolonged observation for recurrent digoxin toxicity after DIGIFAB. Free/unbound digoxin may help assess recurrence; standard total-digoxin assays may mislead until Fab clears, potentially a week or longer in markedly impaired renal function. Total concentrations can rise because bound digoxin is measured. Monitor ECG, blood pressure and potassium; potassium can fall rapidly after reversal. The mirror's general paragraph says especially after the first several hours, whereas its laboratory paragraph says during the first several hours. This timing inconsistency is retained for comparison.

RDM60-rxlist-digoxin-immune-fab-digifab-5deaa55243-C1 · Source locator: Renal failure; General; Laboratory Tests

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

A label mirror is not independent corroboration of its underlying label. See the separately attributed official source; concordance is limited to selected sections.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/digifab-drug/
Retrieved
2026-09-10
Renal-function method
Qualitative severe renal failure; no CrCl interval or reduction schedule
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
ce30ab1f6637da50b844f6052fec356f484597b74def721fab8ef8e52c2c91e7

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/digifab-drug/
Source retrieval
2026-09-10. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
a83901698c2ca22baeb53a1fdb65a87f89704efe3e8c04208e2e653082bd8469
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report